CorMedix, Inc. (NYSE:CRMD) is at least 998.2% than its current record low price of $0.86. There was a 4.3% gain on 3/29/2019 that led the price to move at $9.45. At a recent session, the prices were hovering between $9.07 and $9.62. This company shares are -52.38% up from its target price of $4.5 and the current market capitalization stands at $215.74M. The recent change has given its price a 3.22% lead over SMA 50 and -31.02% deficit over its 52-week high. The stock witnessed 15.24% gains, 44.27% gains and 161.41% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CRMD’s volatility during a week at 12.97% and during a month it has been found around 9.65%.

CorMedix, Inc. (CRMD) Top Holders

Institutional investors currently hold around $30 million or 13.4% in CRMD stock. Look at its top three institutional owners: Elliott Associates, L.P. owns $7.88 million in CorMedix, Inc., which represents roughly 3.65% of the company’s market cap and approximately 26.25% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 827,744 shares of the stock are valued at $7.82 million. The third largest holder is Blackrock Inc., which currently holds $5.02 million worth of this stock and that ownership represents nearly 2.33% of its market capitalization.

CorMedix, Inc. 13F Filings

At the end of December reporting period, 27 institutional holders increased their position in CorMedix, Inc. (NYSE:CRMD) by some 1,193,845 shares, 7 decreased positions by 131,895 and 11 held positions by 1,861,086. That puts total institutional holdings at 3,186,826 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 377,404 shares while 5 institutional investors sold out their entire positions totaling 103,841 shares.

CorMedix, Inc. (CRMD) Analyst Guide

Several analysts have released their opinion on CorMedix, Inc. (NYSE:CRMD), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation [T1].